MX2020010738A - Formulaciones de ciclosporina para uso en el tratamiento del sindrome de bronquiolitis obliterante (bos). - Google Patents

Formulaciones de ciclosporina para uso en el tratamiento del sindrome de bronquiolitis obliterante (bos).

Info

Publication number
MX2020010738A
MX2020010738A MX2020010738A MX2020010738A MX2020010738A MX 2020010738 A MX2020010738 A MX 2020010738A MX 2020010738 A MX2020010738 A MX 2020010738A MX 2020010738 A MX2020010738 A MX 2020010738A MX 2020010738 A MX2020010738 A MX 2020010738A
Authority
MX
Mexico
Prior art keywords
bos
treatment
bronchiolitis obliterans
obliterans syndrome
composition
Prior art date
Application number
MX2020010738A
Other languages
English (en)
Inventor
Oliver Denk
Gerhard Börner
Aldo Iacono
Original Assignee
Breath Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breath Therapeutics Gmbh filed Critical Breath Therapeutics Gmbh
Publication of MX2020010738A publication Critical patent/MX2020010738A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición que comprende ciclosporina A (CsA) para uso en la prevención del síndrome de bronquiolitis obliterante (BOS) en un paciente con trasplante de doble PULMON, o para el tratamiento de BOS o para la prevención o retraso de la progresión de BOS en un paciente con trasplante de doble pulmón al que se le ha diagnosticado con BOS, en el que la composición se administra a dicho paciente mediante la inhalación de dicha composición en forma de aerosol que comprende una dosis terapéuticamente eficaz de ciclosporina A.
MX2020010738A 2018-04-11 2019-04-09 Formulaciones de ciclosporina para uso en el tratamiento del sindrome de bronquiolitis obliterante (bos). MX2020010738A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656226P 2018-04-11 2018-04-11
EP18172067 2018-05-14
PCT/EP2019/058958 WO2019197406A1 (en) 2018-04-11 2019-04-09 Cyclosporine formulations for use in the treatment of bronchiolitis obliterans syndrome (bos)

Publications (1)

Publication Number Publication Date
MX2020010738A true MX2020010738A (es) 2020-11-09

Family

ID=66049232

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010738A MX2020010738A (es) 2018-04-11 2019-04-09 Formulaciones de ciclosporina para uso en el tratamiento del sindrome de bronquiolitis obliterante (bos).

Country Status (13)

Country Link
US (3) US11484566B2 (es)
EP (2) EP3773664B1 (es)
JP (2) JP2021520396A (es)
CN (1) CN112105374A (es)
AU (1) AU2019253137A1 (es)
BR (1) BR112020020564A2 (es)
CA (1) CA3094891A1 (es)
CO (1) CO2020013427A2 (es)
DK (1) DK3773664T3 (es)
IL (1) IL277253B2 (es)
LT (1) LT3773664T (es)
MX (1) MX2020010738A (es)
WO (1) WO2019197406A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3069711A1 (en) * 2015-03-16 2016-09-21 PARI Pharma GmbH Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection
DK3773664T3 (da) * 2018-04-11 2024-06-17 Breath Therapeutics Gmbh Formulering af cyclosporin til anvendelse i behandling af bronchiolitis obliterans syndrom (bos)
US10736847B2 (en) * 2018-07-03 2020-08-11 Becton, Dickinson And Company Inverting device for liposome preparation by centrifugation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2003035030A1 (en) 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
EP3069711A1 (en) * 2015-03-16 2016-09-21 PARI Pharma GmbH Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection
DK3773664T3 (da) * 2018-04-11 2024-06-17 Breath Therapeutics Gmbh Formulering af cyclosporin til anvendelse i behandling af bronchiolitis obliterans syndrom (bos)

Also Published As

Publication number Publication date
IL277253B1 (en) 2023-12-01
US11701403B2 (en) 2023-07-18
US20230364182A1 (en) 2023-11-16
AU2019253137A1 (en) 2020-11-05
US20230128855A1 (en) 2023-04-27
DK3773664T3 (da) 2024-06-17
CN112105374A (zh) 2020-12-18
JP2024069355A (ja) 2024-05-21
EP3773664B1 (en) 2024-05-01
JP2021520396A (ja) 2021-08-19
US11484566B2 (en) 2022-11-01
LT3773664T (lt) 2024-06-10
EP4400119A2 (en) 2024-07-17
BR112020020564A2 (pt) 2021-01-12
US20210077573A1 (en) 2021-03-18
CO2020013427A2 (es) 2020-11-10
CA3094891A1 (en) 2019-10-17
EP3773664A1 (en) 2021-02-17
IL277253B2 (en) 2024-04-01
IL277253A (en) 2020-10-29
WO2019197406A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
WO2020086759A3 (en) Composition and method for treating the lungs
MX2020010738A (es) Formulaciones de ciclosporina para uso en el tratamiento del sindrome de bronquiolitis obliterante (bos).
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
NZ702800A (en) Methods and compositions for cns delivery of heparan n-sulfatase
MX2019012884A (es) Terapia de combinacion.
MX369385B (es) Productos para cicatrizar heridas tisulares.
MX2016009349A (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
RU2017115670A (ru) Лечение инфекции рсв
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2019002284A (es) Sistemas de deposito que comprenden acetato de glatiramer.
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2020007971A (es) Composiciones y metodos para tratar edema pulmonar o inflamacion pulmonar.
MX2021001227A (es) Composicion que contiene un agente mucolitico para el tratamiento de hipersecrecion de moco y un dispositivo para su dosificacion.
MX2022000143A (es) Metodos novedosos.
PH12018502521A1 (en) Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
EA201791525A3 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
MY193963A (en) Composition for treating joint diseases and kit containing same
EA201991531A1 (ru) Способы лечения композициями линаклотида с отсроченным высвобождением